JP2006508665A - 化学療法剤の活性を変化させるブチリルコリンエステラーゼ変異体 - Google Patents

化学療法剤の活性を変化させるブチリルコリンエステラーゼ変異体 Download PDF

Info

Publication number
JP2006508665A
JP2006508665A JP2004557611A JP2004557611A JP2006508665A JP 2006508665 A JP2006508665 A JP 2006508665A JP 2004557611 A JP2004557611 A JP 2004557611A JP 2004557611 A JP2004557611 A JP 2004557611A JP 2006508665 A JP2006508665 A JP 2006508665A
Authority
JP
Japan
Prior art keywords
butyrylcholinesterase
seq
acid sequence
amino acid
butyrylcholinesterase variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004557611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508665A5 (cg-RX-API-DMAC7.html
Inventor
ジェフリー・ディ・ワトキンズ
ジェイムズ・ディ・パンクック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Molecular Evolution Inc
Original Assignee
Applied Molecular Evolution Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Evolution Inc filed Critical Applied Molecular Evolution Inc
Publication of JP2006508665A publication Critical patent/JP2006508665A/ja
Publication of JP2006508665A5 publication Critical patent/JP2006508665A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004557611A 2002-12-04 2003-12-04 化学療法剤の活性を変化させるブチリルコリンエステラーゼ変異体 Pending JP2006508665A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31066602A 2002-12-04 2002-12-04
PCT/US2003/038684 WO2004050041A2 (en) 2002-12-04 2003-12-04 Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents

Publications (2)

Publication Number Publication Date
JP2006508665A true JP2006508665A (ja) 2006-03-16
JP2006508665A5 JP2006508665A5 (cg-RX-API-DMAC7.html) 2007-02-01

Family

ID=32468084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004557611A Pending JP2006508665A (ja) 2002-12-04 2003-12-04 化学療法剤の活性を変化させるブチリルコリンエステラーゼ変異体

Country Status (9)

Country Link
US (1) US20080213281A1 (cg-RX-API-DMAC7.html)
EP (1) EP1581253A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006508665A (cg-RX-API-DMAC7.html)
CN (1) CN100341568C (cg-RX-API-DMAC7.html)
AU (1) AU2003298920A1 (cg-RX-API-DMAC7.html)
BR (1) BR0316865A (cg-RX-API-DMAC7.html)
CA (1) CA2507626A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05005996A (cg-RX-API-DMAC7.html)
WO (1) WO2004050041A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
EP2049661A4 (en) * 2006-08-04 2012-07-04 Pharmathene Inc RECOMBINANT BUTYRYLCHOLINESTERASE WITH LONG HALF-LIFE
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
WO2009139905A2 (en) * 2008-05-16 2009-11-19 Nektar Therapeutics Conjugates of a cholinesterase moiety and a polymer
CA2784861A1 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
CN103898101B (zh) * 2012-12-27 2017-08-08 上海桀蒙生物技术有限公司 利用转基因动物乳腺生物平台大规模生产重组人丁酰胆碱酯酶的方法
CN104630177A (zh) * 2013-11-08 2015-05-20 中国农业大学 一种利用人丁酰胆碱酯酶迷你基因在乳腺中表达重组人丁酰胆碱脂酶的方法
EP3719123A1 (en) 2014-04-29 2020-10-07 Mayo Foundation for Medical Education and Research Uses of butyrylcholinesterase variants having an enhanced ability to hydrolyze acyl-ghrelin
WO2018053216A1 (en) * 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518022A (ja) * 1998-06-16 2002-06-25 ノヴァ モレキュラー インク. Bche遺伝子型の決定による神経疾患の治療法
US20020119489A1 (en) * 2000-12-26 2002-08-29 Oksana Lockridge Butyrylcholinesterase variants and methods of use
US20030153062A1 (en) * 2001-12-20 2003-08-14 Watkins Jeffry D. Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
JP2004535155A (ja) * 2000-12-26 2004-11-25 アプライド モレキュラー エボリューション,インコーポレイテッド 増大した触媒効率を有するブチリルコリンエステラーゼポリペプチド改変体およびその使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1008049A1 (en) * 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264563A (en) * 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5506125A (en) * 1993-12-22 1996-04-09 Agracetus, Inc. Gene delivery instrument with replaceable cartridges
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US6001625A (en) * 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
CN1331339A (zh) * 2000-06-26 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人dna拓扑异构酶i11.44和编码这种多肽的多核苷酸
US7049121B2 (en) * 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518022A (ja) * 1998-06-16 2002-06-25 ノヴァ モレキュラー インク. Bche遺伝子型の決定による神経疾患の治療法
US20020119489A1 (en) * 2000-12-26 2002-08-29 Oksana Lockridge Butyrylcholinesterase variants and methods of use
JP2004535155A (ja) * 2000-12-26 2004-11-25 アプライド モレキュラー エボリューション,インコーポレイテッド 増大した触媒効率を有するブチリルコリンエステラーゼポリペプチド改変体およびその使用方法
US20030153062A1 (en) * 2001-12-20 2003-08-14 Watkins Jeffry D. Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use

Also Published As

Publication number Publication date
US20080213281A1 (en) 2008-09-04
CA2507626A1 (en) 2004-06-17
CN1720063A (zh) 2006-01-11
CN100341568C (zh) 2007-10-10
AU2003298920A1 (en) 2004-06-23
WO2004050041A2 (en) 2004-06-17
MXPA05005996A (es) 2006-04-18
EP1581253A2 (en) 2005-10-05
EP1581253A4 (en) 2007-02-14
WO2004050041A3 (en) 2004-10-28
BR0316865A (pt) 2005-10-25

Similar Documents

Publication Publication Date Title
US20220378833A1 (en) Dimerization switches and uses thereof
US20050136044A1 (en) Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
CA3083499C (en) METHODS OF TREATMENT WITH ASPARAGINASE
ES2465996T3 (es) Métodos y composiciones para la inactivación genética
JP5507242B2 (ja) 酵素補充療法用医薬組成物
KR102822683B1 (ko) 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
EP0879288A1 (fr) Variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
KR20010040257A (ko) 세포주기의 g2/m 상전이에 필수적인 hiv-1 vpr에대한 세포 수용체
US20080213281A1 (en) Butyrylcholinesterase Variants that Alter the Activity of Chemotherapeutic Agents
JP7744621B2 (ja) 切断されたモルモットl-アスパラギナーゼバリアントおよび使用の方法
TW201026333A (en) Human beta-glucuronidase mutants with elevated enzymatic activity under physiological conditions and method for identifying such
KR102579284B1 (ko) 신규의 cd47 바인더와 폴리뉴클레오티드를 포함하는 암 치료를 위한 리포좀 복합체
JP2006522611A (ja) より優れた触媒効果を持つブチリルコリンエステラーゼ変異体ポリペプチド及び使用方法
US9023343B2 (en) Phosphorylation-inhibiting agent or dephosphorylating agent for PTEN
US20040121970A1 (en) Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
JP4252311B2 (ja) 増大した触媒効率を有するブチリルコリンエステラーゼポリペプチド改変体およびその使用方法
TW200804601A (en) A novel and highly functional enzyme obtained by converting a substrate specificity of an enzyme
WO2013020366A1 (zh) 乙酰胆碱酯酶作为核酸酶的应用
AU2002248256A1 (en) Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
US8124393B2 (en) Compositions and methods for inducing or inhibiting activities of selected human cells
US7060456B2 (en) Regulation of human protein phosphatase IIc-like enzyme
WO2020165570A1 (en) Methods relating to disrupting the binding of af9 partner proteins to af9 and/or enl
WO2024238723A1 (en) Methods and compositions for modulating pcsk9 expression
FR2751988A1 (fr) Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
Ramos et al. s4 Journal of Cystic Fibrosis 2 (2003) S3–S12

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100615